Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideyuki Harada

Showing results (81-90 of 160) with videos related to

Pageof 16
Sort By:
Japanese Journal of Clinical Oncology|September 2, 2020
A phase II study of palliative radiotherapy combined with zoledronic acid hydrate for metastatic bone tumour from renal cell carcinomaHideyuki Harada, Naoto Shikama, Hitoshi Wada, et al.
Radiation Oncology (London, England)|March 18, 2021
Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalitiesHaruki Kobayashi, Kazushige Wakuda, Tateaki Naito, et al.
Clinical Lung Cancer|April 2, 2013
Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancerHideyuki Harada, Makoto Nishio, Haruyasu Murakami, et al.
Journal of Radiation Research|December 15, 2015
Reirradiation of spinal metastases with intensity-modulated radiation therapy: an analysis of 23 patientsShohei Kawashiro, Hideyuki Harada, Hirohisa Katagiri, et al.
Japanese Journal of Clinical Oncology|December 11, 2012
Chemoradiotherapy for limited-disease small-cell lung cancer in elderly patients aged 75 years or olderTakehito Shukuya, Toshiaki Takahashi, Hideyuki Harada, et al.
Journal of Cancer|June 14, 2018
Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With ChemoradiotherapyHaruki Kobayashi, Tateaki Naito, Katsuhiro Omae, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 13, 2010
Analysis of dose-volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancerHirofumi Asakura, Takayuki Hashimoto, Sadamoto Zenda, et al.
Radiation Oncology (London, England)|November 5, 2013
Assessment of organ dose reduction and secondary cancer risk associated with the use of proton beam therapy and intensity modulated radiation therapy in treatment of neuroblastomasHiroshi Fuji, Uwe Schneider, Yuji Ishida, et al.
BMC Cancer|January 16, 2014
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapyHiroaki Akamatsu, Keita Mori, Tateaki Naito, et al.
Japanese Journal of Clinical Oncology|June 18, 2026
A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART)Kota Kawabata, Fumiharu Ohka, Ryuta Saito, et al.
Pageof 16

Showing results (81-90 of 160) with videos related to

Sort By:
Pageof 16
Japanese Journal of Clinical Oncology|September 2, 2020
A phase II study of palliative radiotherapy combined with zoledronic acid hydrate for metastatic bone tumour from renal cell carcinomaHideyuki Harada, Naoto Shikama, Hitoshi Wada, et al.
Radiation Oncology (London, England)|March 18, 2021
Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalitiesHaruki Kobayashi, Kazushige Wakuda, Tateaki Naito, et al.
Clinical Lung Cancer|April 2, 2013
Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancerHideyuki Harada, Makoto Nishio, Haruyasu Murakami, et al.
Journal of Radiation Research|December 15, 2015
Reirradiation of spinal metastases with intensity-modulated radiation therapy: an analysis of 23 patientsShohei Kawashiro, Hideyuki Harada, Hirohisa Katagiri, et al.
Japanese Journal of Clinical Oncology|December 11, 2012
Chemoradiotherapy for limited-disease small-cell lung cancer in elderly patients aged 75 years or olderTakehito Shukuya, Toshiaki Takahashi, Hideyuki Harada, et al.
Journal of Cancer|June 14, 2018
Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With ChemoradiotherapyHaruki Kobayashi, Tateaki Naito, Katsuhiro Omae, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 13, 2010
Analysis of dose-volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancerHirofumi Asakura, Takayuki Hashimoto, Sadamoto Zenda, et al.
Radiation Oncology (London, England)|November 5, 2013
Assessment of organ dose reduction and secondary cancer risk associated with the use of proton beam therapy and intensity modulated radiation therapy in treatment of neuroblastomasHiroshi Fuji, Uwe Schneider, Yuji Ishida, et al.
BMC Cancer|January 16, 2014
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapyHiroaki Akamatsu, Keita Mori, Tateaki Naito, et al.
Japanese Journal of Clinical Oncology|June 18, 2026
A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART)Kota Kawabata, Fumiharu Ohka, Ryuta Saito, et al.
Pageof 16